Neoadjuvant Therapy for Urologic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 1866
Special Issue Editors
2. Department of Surgery, University of Melbourne, Melbourne, VIC 3052, Australia
3. Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
4. Department of Urology, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia
Interests: prostate cancer; urologic oncology; registry-based research; radical prostatectomy; clinical trials
Special Issue Information
Dear Colleagues,
Neoadjuvant therapy plays a crucial role in optimizing surgical outcomes and improving survival in urologic malignancies. By integrating historical insights, biological mechanisms, and future directions, this Special Issue will explore the evolving landscape of neoadjuvant strategies in urologic oncology.
We invite original research articles and reviews that address key developments in this field, including novel therapeutic approaches, biomarkers for response prediction, and clinical trial outcomes. Topics may also include mechanistic insights and translational advances.
We look forward to your contributions to this important discussion on the future of neoadjuvant therapy in urologic oncology.
Dr. Marlon Perera
Guest Editor
Dr. David Chen
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urologic oncology
- neoadjuvant therapy
- treatment
- improved survival
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
